FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3121008081> ?p ?o ?g. }

• W3121008081 endingPage "S530" @default.
• W3121008081 startingPage "S529" @default.
• W3121008081 abstract "Abstract Background Treatment for people living with HIV (PLWH) and end stage renal disease (ESRD) on hemodialysis (HD) has previously required complex dose-adjusted regimens. We evaluated a daily regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) and established this treatment as effective and safe, showing that daily TAF resulted in lower plasma tenofovir exposure than a historical comparison of once weekly tenofovir disoproxil fumarate in patients with ESRD on HD. After week (W) 96, participants transitioned to daily B/F/TAF to assess whether efficacy and safety would be maintained on this STR that is guidelines-recommended for PLWH with eGFR &gt; 30 mL/min. Methods Virologically suppressed adult PLWH with ESRD on chronic HD who completed W96 on E/C/F/TAF enrolled in the B/F/TAF extension for 48 weeks. Efficacy was assessed as the proportion of participants with virologic suppression (HIV RNA &lt; 50 copies/mL). Safety was assessed throughout the study, PK was assessed using sparse sampling at W4, 24 and 48. Results 55 enrolled, 36 completed E/C/F/TAF, 10 entered the B/F/TAF extension. The median age was 55 yrs (range 34-63); median time on HD was 4 yrs (range 2-16). All ten participants on B/F/TAF had HIV-1 RNA &lt; 50 c/mL (95% CI 69%, 100%) at W48. All participants had at least 1 adverse event (AE); most were grade 1 or 2 in severity. One participant had a grade 3 AE and 3 had serious AEs; none were considered related to study drug by the investigator. One participant had AEs attributed to study drug (malaise grade 1 and nausea grade 2), which resolved and did not lead to discontinuation of study drug. There were no clinically relevant changes in fasting lipids. In participants with evaluable data (n=2-5 per timepoint), mean bictegravir trough concentrations were lower compared to PLWH not on HD but remained 4- to 7-fold higher than the established protein-adjusted 95% effective concentration (paEC95) of 162 ng/mL against wild-type virus. Conclusion A once daily regimen of B/F/TAF maintained virologic suppression in PLWH on chronic HD. B/F/TAF was well-tolerated with no discontinuations. B/F/TAF may be an effective, safe and convenient once daily STR and ameliorate the need for dose adjustment in appropriate PLWH who require chronic HD. Disclosures Joseph J. Eron, MD, Gilead Sciences (Consultant, Research Grant or Support)Janssen (Consultant, Research Grant or Support)Merck (Consultant)ViiV Healthcare (Consultant, Research Grant or Support) Aimee Wilkin, MD, MPH, Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member)GlaxoSmithKline (Grant/Research Support)Janssen (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member)Pfizer (Grant/Research Support) Moti Ramgopal, MD FACP FIDSA, AbbVie (Speaker’s Bureau)Allergan (Speaker’s Bureau)Gilead Sciences Inc. (Consultant, Scientific Research Study Investigator, Speaker’s Bureau)Janssen (Speaker’s Bureau)Merck (Consultant)Viiv Healthcare (Consultant) Olayemi Osiyemi, M.D, GlaxoSmithKline (Advisor or Review Panel member, Speaker’s Bureau)ViiV Healthcare (Advisor or Review Panel member, Speaker’s Bureau) Jihad Slim, MD, Abbvie (Speaker’s Bureau)Gilead (Speaker’s Bureau)Jansen (Speaker’s Bureau)Merck (Speaker’s Bureau)ViiV (Speaker’s Bureau) David Asmuth, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Edwin DeJesus, MD, Gilead Sciences (Advisor or Review Panel member) Polina German, PharmD, Gilead Sciences (Employee) Christiana Blair, MS, Gilead Sciences (Employee, Shareholder) Christoph C. Carter, MD, Gilead Sciences Inc. (Employee, Shareholder) Diana M. Brainard, MD, Gilead Sciences (Employee) Sean E. Collins, MD, MS, Gilead Sciences (Employee) Hal Martin, MD, MPH, Gilead Sciences Inc. (Employee, Shareholder)" @default.
• W3121008081 created "2021-01-18" @default.
• W3121008081 creator A5001838238 @default.
• W3121008081 creator A5002969349 @default.
• W3121008081 creator A5005486541 @default.
• W3121008081 creator A5009975917 @default.
• W3121008081 creator A5015389391 @default.
• W3121008081 creator A5024560316 @default.
• W3121008081 creator A5024710603 @default.
• W3121008081 creator A5026987150 @default.
• W3121008081 creator A5042040728 @default.
• W3121008081 creator A5045283992 @default.
• W3121008081 creator A5049071998 @default.
• W3121008081 creator A5065954575 @default.
• W3121008081 creator A5069170911 @default.
• W3121008081 creator A5073519594 @default.
• W3121008081 date "2020-10-01" @default.
• W3121008081 modified "2023-10-16" @default.
• W3121008081 title "1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis" @default.
• W3121008081 doi "https://doi.org/10.1093/ofid/ofaa439.1188" @default.
• W3121008081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7777356" @default.
• W3121008081 hasPublicationYear "2020" @default.
• W3121008081 type Work @default.
• W3121008081 sameAs 3121008081 @default.
• W3121008081 citedByCount "4" @default.
• W3121008081 countsByYear W31210080812022 @default.
• W3121008081 countsByYear W31210080812023 @default.
• W3121008081 crossrefType "journal-article" @default.
• W3121008081 hasAuthorship W3121008081A5001838238 @default.
• W3121008081 hasAuthorship W3121008081A5002969349 @default.
• W3121008081 hasAuthorship W3121008081A5005486541 @default.
• W3121008081 hasAuthorship W3121008081A5009975917 @default.
• W3121008081 hasAuthorship W3121008081A5015389391 @default.
• W3121008081 hasAuthorship W3121008081A5024560316 @default.
• W3121008081 hasAuthorship W3121008081A5024710603 @default.
• W3121008081 hasAuthorship W3121008081A5026987150 @default.
• W3121008081 hasAuthorship W3121008081A5042040728 @default.
• W3121008081 hasAuthorship W3121008081A5045283992 @default.
• W3121008081 hasAuthorship W3121008081A5049071998 @default.
• W3121008081 hasAuthorship W3121008081A5065954575 @default.
• W3121008081 hasAuthorship W3121008081A5069170911 @default.
• W3121008081 hasAuthorship W3121008081A5073519594 @default.
• W3121008081 hasBestOaLocation W31210080811 @default.
• W3121008081 hasConcept C126322002 @default.
• W3121008081 hasConcept C142462285 @default.
• W3121008081 hasConcept C159047783 @default.
• W3121008081 hasConcept C2777068322 @default.
• W3121008081 hasConcept C2778063415 @default.
• W3121008081 hasConcept C2778723075 @default.
• W3121008081 hasConcept C2779778239 @default.
• W3121008081 hasConcept C2780524789 @default.
• W3121008081 hasConcept C2781413609 @default.
• W3121008081 hasConcept C2911190787 @default.
• W3121008081 hasConcept C2993143319 @default.
• W3121008081 hasConcept C3013748606 @default.
• W3121008081 hasConcept C3019040382 @default.
• W3121008081 hasConcept C71924100 @default.
• W3121008081 hasConcept C90924648 @default.
• W3121008081 hasConceptScore W3121008081C126322002 @default.
• W3121008081 hasConceptScore W3121008081C142462285 @default.
• W3121008081 hasConceptScore W3121008081C159047783 @default.
• W3121008081 hasConceptScore W3121008081C2777068322 @default.
• W3121008081 hasConceptScore W3121008081C2778063415 @default.
• W3121008081 hasConceptScore W3121008081C2778723075 @default.
• W3121008081 hasConceptScore W3121008081C2779778239 @default.
• W3121008081 hasConceptScore W3121008081C2780524789 @default.
• W3121008081 hasConceptScore W3121008081C2781413609 @default.
• W3121008081 hasConceptScore W3121008081C2911190787 @default.
• W3121008081 hasConceptScore W3121008081C2993143319 @default.
• W3121008081 hasConceptScore W3121008081C3013748606 @default.
• W3121008081 hasConceptScore W3121008081C3019040382 @default.
• W3121008081 hasConceptScore W3121008081C71924100 @default.
• W3121008081 hasConceptScore W3121008081C90924648 @default.
• W3121008081 hasIssue "Supplement_1" @default.
• W3121008081 hasLocation W31210080811 @default.
• W3121008081 hasLocation W31210080812 @default.
• W3121008081 hasLocation W31210080813 @default.
• W3121008081 hasOpenAccess W3121008081 @default.
• W3121008081 hasPrimaryLocation W31210080811 @default.
• W3121008081 hasRelatedWork W2260898675 @default.
• W3121008081 hasRelatedWork W2264012645 @default.
• W3121008081 hasRelatedWork W2543124320 @default.
• W3121008081 hasRelatedWork W2582476650 @default.
• W3121008081 hasRelatedWork W3017099993 @default.
• W3121008081 hasRelatedWork W3130587537 @default.
• W3121008081 hasRelatedWork W3138620867 @default.
• W3121008081 hasRelatedWork W3163676095 @default.
• W3121008081 hasRelatedWork W4238444439 @default.
• W3121008081 hasRelatedWork W2584289553 @default.
• W3121008081 hasVolume "7" @default.
• W3121008081 isParatext "false" @default.
• W3121008081 isRetracted "false" @default.
• W3121008081 magId "3121008081" @default.
• W3121008081 workType "article" @default.